-
Track & Monitor
NewCell & gene therapy in pharma: corneal endothelial cell culturing
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the pharma industry’s corneal endothelial cell culturing within Cell & gene therapy innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned...
-
Sector Analysis
NewPolycystic Ovarian Syndrome (PCOS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in PCOS therapeutics. • More than 54,000,000 total prevalent cases of PCOS are expected in 2024 in the 16 countries covered in GlobalData’s epidemiology forecast for PCOS. • Marketed drugs for PCOS are widely genericized and the majority of drugs indicated to treat PCOS belong to gonadotropin class. • Out of 18 drugs in the pipeline for PCOS, only three are in the Phase III stage of...
-
Sector Analysis
NewFemale Sexual Dysfunction (FSD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in FSD therapeutics. • More than 384,000,000 total prevalent cases of FSD were there in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for FSD. • Marketed drugs for FSD are widely genericized and the majority of drugs indicated to treat FSD are estrogen receptor agonist. • Out of 24 drugs in the pipeline for FSD, only three are in the Phase III stage of...
-
Thematic Analysis
NewPatient Empowerment – Thematic Intelligence
Patient Empowerment Thematic Report Overview Recently, the global healthcare systems have been challenged by the prevalence of chronic disease and the need to support growing aging populations. Therefore, healthcare providers that promote patient empowerment strategies, such as self-care and autonomy in managing health, are being increasingly adopted. Notably, the patient empowerment trend is greatly benefiting from the rise of innovative tools such as wearable devices, as well as the digitalization of healthcare systems, such as the increasing implementation of electronic...
-
Track & Monitor
NewInnovation in pharma: phenotypic drug screening
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the pharma industry’s phenotypic drug screening innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned analysts with deep knowledge and experience...
-
Product Insights
NewLupus Nephritis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Lupus Nephritis Clinical Trial Report Overview A total of 434 lupus nephritis clinical trials were conducted as of February 2024. The lupus nephritis clinical trial report provides a comprehensive understanding of the lupus nephritis clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · Asia-Pacific · North...
-
Product Insights
NewCutaneous Squamous Cell Carcinoma (cSCC) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Cutaneous Squamous Cell Carcinoma (cSCC) Clinical Trial Report Overview A total of 161 cSCC clinical trials were conducted as of February 2024. The cSCC clinical trial report provides a comprehensive understanding of the Cutaneous Squamous Cell Carcinoma clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · ...
-
Product Insights
NewHuman Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Clinical Trial Report Overview A total of 2,230 HER2- breast cancer clinical trials were conducted as of February 2024. The HER2- breast cancer clinical trial report provides a comprehensive understanding of the human epidermal growth factor receptor 2 negative breast cancer clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes...
Testimonial
Your Drugs database is great, you can find all the information you want such as sales forecasts, countries, diseases, dates, clinical trials, and patent expiration. We are using this information to research the leading competitive products in our current project. In addition, we analyze the profiles of the leading products and use this information to set the differentiation profile of our own products and clarify our positioning. In terms of business forecasts, we are able to provide more objective figures by using the Drug Forecast and Market Analysis report series. The analysis of product share by disease (series of Drug Forecast and Market Analysis reports) is used for business feasibility assessment.”
The ability to evaluate or provide information on PJs in R&D from both product and disease perspectives (it is difficult to find a database that can be used comprehensively for both), stands GlobalData out from other providers. The release of new functions such as Likelihood of approval (LoA) analysis, which was something I wanted but did not exist, shows that GlobalData have done a good job of researching the industry and developing services from the customer’s perspective which is another positive.
GlobalData’s COVID-19 Bulletin, which is sent out several times a week, provides the latest information on COVID-19 related vaccines and therapeutics and is used as background information.
“GlobalData provides extensive and comprehensive Pharma and Biotech data along with spectacular customer support. I use their drug, trial and company data on a daily basis to support our sales and marketing efforts.”
“As a global biopharma R&D strategy consultancy, we use the GlobalData Pharma Intelligence platform across a broad spectrum of topics, it provides all key data in one place”